Development

Entera Bio receives favorable feedback on an osteoporosis trial plan

development2026-10-10biotech

Claim

The newsletter reports positive FDA feedback on Entera Bio’s Phase 3 plan for EB613, an oral bone-building osteoporosis treatment in development; this is feedback on a trial plan, not drug approval.

Reporting date: 2026-10-10 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to October 10, 2026 (theinnermostloop.substack.com)
Source linked by the October 10 issue (www.globenewswire.com)

Indexed from Dr. Alex Wissner-Gross’s October 10, 2026 edition. This is an attributed summary; linked-source claims have not been independently verified.

Knowledge graphopen in browser →

Reported in

Welcome to October 10, 2026

Actor

Entera Bio

Referenced by

Welcome to October 10, 2026

Cite or correct this record

Citation formatCitation text

Entera Bio receives favorable feedback on an osteoporosis trial plan
Innermost Loop KB — secondary record
Reporting date: 2026-10-10
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-10-10-eb613-plan
Claim: The newsletter reports positive FDA feedback on Entera Bio’s Phase 3 plan for EB613, an oral bone-building osteoporosis treatment in development; this is feedback on a trial plan, not drug approval.
Attributed sources:
- Welcome to October 10, 2026 — https://theinnermostloop.substack.com/p/welcome-to-october-10-2026
- Source linked by the October 10 issue — https://www.globenewswire.com/news-release/2026/06/22/3315282/0/en/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613-the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosi.html
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.